Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))

K. Hotta, S. Saeki, M. Yamaguchi, D. Harada, A. Bessho, K. Tanaka, K. Inoue, K. Gemba, M. Shiojiri, Y. Kato, T. Ninomiya, T. Kubo, J. Kishimoto, Y. Shioyama, Kuniaki Katsui, J. Sasaki, K. Kiura, K. Sugio

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))'. Together they form a unique fingerprint.

Medicine & Life Sciences